Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Base Year Market Size (2025) | USD 1.86 Billion |
| Market Size (2026) | USD 1.99 Billion |
| Market Size (2031) | USD 2.82 Billion |
| Growth Rate (2026 - 2031) | 7.18% CAGR |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Japan Diabetes Devices Market Analysis by Mordor Intelligence
The Japan Diabetes Devices Market size in 2026 is estimated at USD 1.99 billion, growing from 2025 value of USD 1.86 billion with 2031 projections showing USD 2.82 billion, growing at 7.18% CAGR over 2026-2031.
The Japan Diabetes Devices Market size is estimated at USD 1.86 billion in 2025, and is expected to reach USD 2.63 billion by 2030, at a CAGR of 7.26% during the forecast period (2025-2030).
An immune system malfunction causes type 1 diabetes, and Type 2 diabetes is linked to leading a sedentary lifestyle, which results in the development of inherent resistance to insulin. Hence, Type 1 diabetes can be characterized as insulin-requiring, while Type 2 diabetes can be described as insulin-dependent diabetes.
Japan has one of the largest elderly populations in the world, which is more susceptible to the onset of type 2 diabetes. As Japan's population continues to age, the prevalence of diabetes increases as well. The monitoring and management of blood glucose levels are on the rise, as they help avoid negative consequences, such as cardiovascular diseases, kidney disorders, and many other conditions.
The rising prevalence of diabetes in Japan has become a significant health concern, driving the demand for diabetes devices. With lifestyle changes, including sedentary behavior, unhealthy eating habits, and an aging population, Italy has witnessed a steady increase in the number of individuals diagnosed with diabetes. According to recent statistics, japan ranks among the Asia countries with a high prevalence of diabetes, with both type 1 and type 2 diabetes contributing to the burden of the disease.
As the diabetes population continues to grow in Japan, there is a parallel surge in the need for effective management and treatment options. Diabetes devices play a crucial role in controlling blood sugar levels and preventing complications associated with diabetes. These medications are favored by many patients due to their convenience, ease of administration, and ability to improve glycemic control.
The demand for diabetes devices reflects the necessity for accessible and efficient treatments to combat the escalating diabetes epidemic in Japan.
Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Japan Diabetes Devices Market Trends and Insights
The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period
To use a CGM, a small sensor is inserted into the abdomen or arm with a tiny plastic cannula penetrating the top skin layer. An adhesive patch holds the sensor in place, allowing it to take glucose readings in interstitial fluid throughout the day and night. Generally, the sensors must be replaced every 7 to 14 days. A small, reusable transmitter connected to the sensor allows the system to send real-time readings wirelessly to a monitor device that displays blood glucose data. Some systems contain a dedicated monitor, and some display the information via a smartphone app.
Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing.
Some technologies with high potential in continuous glucose sensing are reported, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, presents a much longer lifespan than electrochemical sensors. Technological advancements to improve the sensor's accuracy are expected to drive segment growth during the forecast period.
The frequency of monitoring glucose levels depends on the diabetes type, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels regularly to monitor their blood glucose levels and adjust the insulin dosing accordingly. The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals.
Furthermore, the current continuous glucose monitoring devices can either retrospectively display the trends in blood glucose levels by downloading the data or give a real-time picture of glucose levels through receiver displays. Continuous glucose monitoring devices are becoming cheaper with new technologies, like cell phone integration. It is likely to drive the segment growth during the forecast period.
Insulin cartridges in reusable pens occupied the highest share in the management devices segment in the current year
Insulin cartridges in reusable pens occupied the highest market share of about 68% in the management devices segment in the current year.
Insulin cartridges in reusable pens are an upgraded version of insulin vials. Most types of insulins are manufactured in the form of cartridges, making them easily accessible. These devices include all the functional benefits of reusable pens and are cost-effective, as these cartridges are less expensive compared to disposable insulin pens in the long run.
Due to the increasing demand for insulin cartridges, most insulin device manufacturers produced reusable insulin pens compatible with various insulin manufacturers' cartridges. These insulin cartridges are considered more consumer-friendly, as they are smaller and less noticeable than the classic vial-and-syringe.
These devices are also more portable for consumers. Open cartridges do not need to be refrigerated, making storage easy for consumers. Thus, cartridges are the most cost-effective insulin use, as reusable pens are a one-time investment, unlike disposable pens.
Diabetes is identified as a healthcare priority by the Ministry of Health, Labour, and Welfare. The high prevalence of type 2 diabetes is associated with a significant economic burden. The costs of diabetes are increased in patients with co-morbidities such as hypertension and hyperlipidemia and in patients who develop complications.
Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and people with diabetes can visit doctors freely in Japan. Also, insulin therapy by self-injection became legal and is covered by health insurance. Such advantages helped the adoption of these products in the Japanese market.
Competitive Landscape
The Japanese diabetes devices market is consolidated, with major manufacturers like Roche, Abbott, Novo Nordisk, Dexcom, Medtronic, etc., and other region-specific manufacturers.
Japan Diabetes Devices Industry Leaders
Abbott Diabetes Care
Medtronic PLC
Novo Nordisk A/S
Roche Diabetes Care
Dexcom Inc.
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Product refresh cycles in continuous glucose monitoring, along with a shift toward integrated diabetes management systems (CGM plus automated insulin delivery), are creating room for manufacturers that can bundle sensors, transmitters/receivers, and supporting software into a single offering. In Japan, PMDA and MHLW clarified the regulatory path for digital components under the PMD Act. The 2024 DASH for SaMD 2 policy also formalizes a centralized SaMD consultation and review process, supporting earlier classification decisions and development planning for connected CGM, dosing software, and other software-enabled features.
A commercial opportunity is coordinating regulatory clearance with access under Japan's separate National Health Insurance reimbursement assessment, which reviews clinical and cost effectiveness after approval. Evidence of movement toward advanced systems shows PMDA-regulated adoption steps for next-generation CGM and automated insulin delivery, alongside payer considerations for pediatric indications and integrated dosing workflows. Companies that can show system-level performance for combination drug-device and device-software configurations, while also preparing reimbursement-ready evidence packages, should be able to reduce the time from approval to routine use in clinical practice.
Recent Industry Developments
- July 2026: MiniMed Japan reported regulatory approval in Japan for the MiniMed 780G system's SmartGuard function with an expanded indicated age range, extending use from children aged 7 years and older down to 2 years and older. Broadening pediatric eligibility expands the installed base for automated insulin delivery and increases demand for compatible CGM and pump consumables across pediatric diabetes care pathways.
- June 2026: MiniMed (Medtronic) and Abbott announced a strategic alliance to co-develop and commercialize next-generation dual glucose-ketone sensing for integrated automated insulin delivery systems. The collaboration places more emphasis on metabolic risk detection alongside glucose monitoring and aligns sensing with automated dosing platforms. It may support broader safety and management feature sets across pediatric and adult care pathways.
- March 2024: Abbott Japan launched FreeStyle Libre 2 in Japan with real-time glucose measurement and alert functionality, with coverage under Japan's national health insurance system. The launch supports broader CGM penetration beyond scan-only workflows and reinforces payer-backed adoption of connected monitoring features in routine diabetes management.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers diabetes care devices sold and used in Japan for monitoring blood glucose and for insulin delivery, including the related disposable consumables needed for routine use.
Scope exclusions: We exclude diabetes drugs, general hospital diagnostic equipment not specific to diabetes care, and broader wellness wearables that do not provide diabetes monitoring or insulin delivery.
Segmentation Overview
- Management Devices
- Insulin Pump
- Technology
- Tethered Insulin Pump
- Tubeless Insulin Pump
- Component
- Insulin Pump Device
- Insulin Pump Reservoir
- Infusion Set
- Technology
- Insulin pens
- Cartridges in Reusable Pens
- Insulin Disposable Pens
- Insulin Syringes
- Jet Injectors
- Insulin Pump
- Monitoring Devices
- Self-monitoring Blood Glucose
- Glucometer Devices
- Blood Glucose Test Strips
- Lancets
- Continuous Glucose Monitoring
- Sensors
- Durables (Receivers and Transmitters)
- Self-monitoring Blood Glucose
Data Sources, Market Sizing, and Validation
Desk Research
Desk research was used to build the starting shape of the Japan demand pool and the pricing bands that are realistic for devices and consumables. We mainly referenced public health statistics and reimbursement signals, since they help explain how many people are treated, how often monitoring happens, and how device adoption changes over time.
Sources we reviewed include, for example, Japan health ministry publications, OECD health statistics, World Health Organization diabetes indicators, International Diabetes Federation country profiles, and customs trade statistics for relevant device categories. We also used company annual reports, investor presentations, product labeling information, and reputable press releases to cross-check product launches and replacement cycles. In a few places, paid subscriptions for company financials and news were used to confirm reported revenue direction and major events, and a patent database was used to sense innovation intensity. These sources are illustrative only, and many other public references were consulted for data collection, validation, and clarification.
Primary Interviews and Surveys
Primary work focused on validating what is actually purchased and used in Japan across monitoring and insulin delivery, since that is where desk sources can run broad. We spoke with a mix of manufacturers and channel participants, along with clinicians and diabetes educators, to confirm usage frequency for test strips and sensors, typical replacement timing for pumps and pens, and the pace of continuous glucose monitoring adoption. To keep assumptions grounded, insights were checked across major demand centers in Japan and across different care settings that influence prescribing and refills.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 38% | CXOs: 15% | |
| Mid tier: 40% | Functional/Unit leaders: 36% | |
| Smaller Players: 22% | Managers: 49% |
Market-Sizing & Forecasting
Our sizing starts from a top-down build that ties Japan diabetes prevalence and treated population to device usage patterns, and then converts that into annual device and consumable demand. For monitoring, the key logic follows testing frequency and refill cycles, and for CGM it follows sensor change intervals and the installed base of users. For insulin delivery, the model tracks the user pool on insulin therapy and the split across pens, pumps, and other delivery formats.
Several inputs act as practical anchors, such as the number of people diagnosed with diabetes in Japan, treatment share and insulin usage rates, CGM penetration and growth, average test strips used per user per month, sensor replacement frequency, and typical replacement cycles for durable items like receivers, transmitters, and pumps. After the top-down totals are formed, selective bottom-up checks are done using supplier revenue direction, sampled average selling price ranges multiplied by estimated volumes, and channel feedback on annual unit movement, which helps correct any obvious gaps. When product-level data is missing, we interpolate using adjacent-year adoption trends and confirmed replacement cycles, followed by a re-check with interview inputs.
For forecasting, we rely on scenario analysis supported by a simple multivariate regression on adoption drivers, which are then adjusted using expert expectations about reimbursement, technology shifts from SMBG to CGM, and aging-related demand. The final forecast is kept explainable, so each growth change can be traced back to one or two drivers rather than a complex model that is hard to repeat.
Data Validation & Update Cycle
Validation is done by cross-checking the model against independent signals such as treated population movement, consumable run rates, and the implied installed base growth for CGM and pumps. When a number looks too high or too low, we review the assumption chain, re-check currency timing and price bands, and then re-contact relevant interviewees if the variance is still not explained.
Before sign-off, the build goes through multiple analyst reviews so calculation logic, unit conversions, and year alignment are consistent across device and consumable lines. Reports are refreshed annually, and interim updates are triggered when material events occur, such as reimbursement changes or major product transitions. Right before delivery, a fresh pass is completed so clients receive the latest updated view from the same repeatable steps.
Mordor Intelligence's Japan Diabetes Devices Market Size Compared With Other Published Estimates
Published market sizes for Japan diabetes devices can look different even when they appear to measure the same underlying coverage. In practice, the gaps usually come from what is counted as a device versus a consumable, the exact year used as the base, and how quickly newer monitoring formats are assumed to replace older ones.
Key drivers in this market are how CGM sensors and related durables are treated, whether insulin delivery is limited to pumps and pens or expanded to broader supplies, and how average selling prices are projected as reimbursement and product mix change. Some estimates also stretch the scope by mixing adjacent diabetes care items, or they keep a longer forecast window that amplifies growth through aggressive adoption assumptions and different currency conversion timing.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Mordor Intelligence | USD 1.86 B (2025) | |
| Industry Data Publisher A | USD 1.73 B (2024) | Uses a different base year and can group categories like blood glucose meters, CGM, and insulin delivery under broader device buckets, which can shift what is counted as device revenue versus consumables. |
| Industry Publisher B | USD 1.69 B (2024) | Applies a longer forecast horizon and may assume faster price and mix uplift for newer monitoring formats, and it can treat strip and lancet consumption assumptions differently, which changes the recurring revenue portion. |
Observed refill rhythms for test strips and CGM sensors, together with adoption checks from interviews, are the evidence used to keep Mordor Intelligence tied to an annual demand pool that is consistent with real usage in Japan. Taken together, the comparison shows that year selection and the handling of recurring consumables versus durables are the main reasons the numbers spread, so aligning scope and usage assumptions is the practical way to interpret any estimate.
Key Questions Answered in the Report
How big is the Japan Diabetes Devices Market?
The Japan Diabetes Devices Market size is expected to reach USD 1.99 billion in 2026 and grow at a CAGR of 7.18% to reach USD 2.82 billion by 2031.
What is the current Japan Diabetes Devices Market size?
In 2026, the Japan Diabetes Devices Market size is expected to reach USD 1.99 billion.
Who are the key players in Japan Diabetes Devices Market?
Abbott Diabetes Care, Medtronic PLC, Novo Nordisk A/S, Roche Diabetes Care and Dexcom Inc. are the major companies operating in the Japan Diabetes Devices Market.
What years does this Japan Diabetes Devices Market cover, and what was the market size in 2025?
In 2025, the Japan Diabetes Devices Market size was estimated at USD 1.99 billion. The report covers the Japan Diabetes Devices Market historical market size for years: 2019, 2020, 2021, 2022, 2023, 2024 and 2025. The report also forecasts the Japan Diabetes Devices Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
